Radiopharm Theranostics Signs Letter of Intent with GenesisCare
corresponding services agreement is currently being negotiated. The term of the initial project is anticipated to be 18 months. The overall cost of the services under the LOI are not considered material and are included in existing budgets and funding. Under the LOI, Radiopharm will deploy its novel radiopharmaceutical (RAD204) targeting PDL/1-positive lung cancer in patients at Australian clinical research centres secured by GenesisCare. It is likely that this will be the first-ever human clinical trial exposure to this Radiopharm compound and, if successful, will set the stage for expanded development in lung cancer patients whose cancer is sensitive to treatment with this type of immunotherapy.